For the quarter ending 2025-09-30, NVAX made $327,429,000 in revenue. -$202,379,000 in net income. Net profit margin of -61.81%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Selling, general, and administrative | - | 43,612,000 | 48,090,000 | - |
| Total revenue | 70,445,000 | 239,240,000 | 666,655,000 | 91,083,000 |
| Cost of sales | 21,496,000 | 15,325,000 | 14,115,000 | 47,939,000 |
| Research and development | 98,274,000 | 79,233,000 | 88,937,000 | 98,529,500 |
| Selling, general, and administrative | 31,655,000 | - | - | 84,296,250 |
| Impairment of assets held for sale | 97,038,000 | - | - | - |
| Total expenses | 248,463,000 | 138,170,000 | 151,142,000 | 229,038,500 |
| Gain on disposition of novavax cz assets | - | - | - | 12,987,250 |
| Income (loss) from operations | -178,018,000 | 101,070,000 | 515,513,000 | -137,955,500 |
| Interest expense | 5,482,000 | 5,518,000 | 5,723,000 | 18,835,250 |
| Loss on debt extinguishment | -28,714,000 | - | - | - |
| Other income, net | 9,178,000 | 11,902,000 | 10,056,000 | 8,394,500 |
| Income (loss) before income tax expense | -203,036,000 | 107,454,000 | 519,846,000 | -109,434,500 |
| Income tax expense (benefit) | -657,000 | 946,000 | 1,200,000 | 4,855,500 |
| Net income (loss) | -202,379,000 | 106,508,000 | 518,646,000 | -114,290,000 |
| Basic (in shares) | 162,353,000 | 162,019,000 | 161,049,000 | -78,119,000 |
| Basic (in usd per share) | -1.25 | 0.66 | 3.22 | -0.78 |
| Diluted (in shares) | 162,353,000 | 177,215,000 | 177,625,000 | -86,857,000 |
| Diluted (in usd per share) | -1.25 | 0.62 | 2.93 | -0.73 |
NOVAVAX INC (NVAX)
NOVAVAX INC (NVAX)